Ironwood Pharmaceuticals (IRWD) Net Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Net Margin across 17 years of filings, most recently posting 45.37% for Q2 2026.

• In Q2 2026, Net Margin rose 1769.0% year-over-year to 45.37%; the TTM figure through Jun 2026 stood at 56.77% (up 2629.0% YoY), while the FY2025 annual figure was 38.88%, up 964.0% from the prior year.
• Net Margin came in at 45.37% for Q2 2026 at Ironwood Pharmaceuticals, up from 38.28% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 186.29% in Q4 2025 to a low of 1014.62% in Q2 2023.
• Average Net Margin over 5 years is 21.68%, with a median of 38.21% recorded in 2022.
• Year-over-year, Net Margin tumbled 105276 bps in 2023 and jumped 101371 bps in 2024.
• Over 5 years, Net Margin stood at 45.58% in 2022, then climbed by 1 bps to 46.21% in 2023, then surged by 149 bps to 115.05% in 2024, then soared by 62 bps to 186.29% in 2025, then sank by 76 bps to 45.37% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 45.37% in Q2 2026, 38.28% in Q1 2026, and 186.29% in Q4 2025.